Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AVITA Medical (RCEL) Research & Development (2018 - 2025)

AVITA Medical filings provide 8 years of Research & Development readings, the most recent being $5.7 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 17.34% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.8 million, a 2.36% increase, with the full-year FY2025 number at $20.8 million, up 2.35% from a year prior.
  • Research & Development hit $5.7 million in Q4 2025 for AVITA Medical, up from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.8 million in Q4 2023 to a low of $3.4 million in Q4 2022.
  • Median Research & Development over the past 5 years was $4.7 million (2023), compared with a mean of $4.7 million.
  • Biggest five-year swings in Research & Development: soared 100.21% in 2023 and later plummeted 30.95% in 2025.
  • AVITA Medical's Research & Development stood at $3.4 million in 2021, then fell by 0.27% to $3.4 million in 2022, then skyrocketed by 100.21% to $6.8 million in 2023, then decreased by 28.31% to $4.8 million in 2024, then grew by 17.34% to $5.7 million in 2025.
  • The last three reported values for Research & Development were $5.7 million (Q4 2025), $3.7 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.